Download PDF
J Pediatr Infect Dis 2018; 13(01): 002-009
DOI: 10.1055/s-0037-1604337
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Pneumocystis jirovecii Pneumonia in Children

Dhulika Dhingra
1   Chacha Nehru Bal Chikitsalaya, New Delhi, India
,
Anirban Mandal
2   Sitaram Bhartia Institute of Science and Research, New Delhi, India
,
Amitabh Singh
3   Vardhaman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
› Author Affiliations
Further Information

Publication History

20 April 2017

19 June 2017

Publication Date:
20 July 2017 (online)

    Permissions and Reprints

Abstract

Pneumocystis jirovecii (previously known as Pneumocystis carinii), a yeast-like, atypical fungus, is an important human pathogen especially in the immunocompromised hosts. It primarily causes pneumonia (P. jirovecii pneumonia or PJP), but rarely can infect other extrapulmonary sites, such as lymph nodes, spleen, liver, and bone marrow. Though an early age of colonization/infection has been documented even in healthy children, children with human immunodeficiency virus (HIV) infection, those with immunosuppression secondary to malignancies, cancer chemotherapy, and other immunosuppressive agents, and primary immunodeficiency are the ones primarily affected with the disease. The mode of presentation is variable depending on the underlying disease, immune status, and age of the patient, but clinical features of PJP are largely nonspecific. Though diffuse, perihilar predominant, bilaterally symmetrical interstitial infiltrates with apical sparing is characteristically seen in pulmonary imaging, it is very difficult to differentiate between PJP and other causes of pneumonia in immunocompromised hosts. The growth of the organism being extremely difficult in the laboratory, direct demonstration of the organism or its DNA in pulmonary secretions (induced sputum, bronchoalveolar lavage [BAL], etc.) by either direct stains or polymerase chain reaction (PCR) is the predominant mode of diagnosis. Chemoprophylaxis is indicated for HIV-infected infants and other children with profound immunosuppression. Co-trimoxazole is the drug of choice for both prophylaxis and therapy in children with PJP; pentamidine, atovaquone, dapsone, and clindamycin/primaquine are other alternatives. Following the advent of highly active antiretroviral therapy (HAART) for the treatment of HIV disease and co-trimoxazole prophylaxis, both the incidence of PJP and associated mortality have decreased dramatically in the developing regions. Developing countries still have very high morbidity and mortality with PJP, especially in HIV-infected children.

Keywords

immunosuppression - HIV/AIDS - Co-trimoxazole
 

  • References

  • 1 Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8 (09) 891-896
    CrossrefPubMedGoogle Scholar
  • 2 Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997; 10 (03) 401-418
    CrossrefPubMedGoogle Scholar
  • 3 Calderon EJ. Epidemiology of Pneumocystis infection in human. J Mycol Med 2009; 19: 270-275
    CrossrefPubMedGoogle Scholar
  • 4 Takahashi T, Goto M, Endo T. , et al. Pneumocystis carinii carriage in immunocompromised patients with and without human immunodeficiency virus infection. J Med Microbiol 2002; 51 (07) 611-614
    CrossrefPubMedGoogle Scholar
  • 5 Gona P, Van Dyke RB, Williams PL. , et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006; 296 (03) 292-300
    CrossrefPubMedGoogle Scholar
  • 6 Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008; 197 (01) 10-17
    CrossrefPubMedGoogle Scholar
  • 7 Larsen HH, von Linstow ML, Lundgren B, Høgh B, Westh H, Lundgren JD. Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg Infect Dis 2007; 13 (01) 66-72
    CrossrefPubMedGoogle Scholar
  • 8 Monroy-Vaca EX, de Armas Y, Illnait-Zaragozí MT. , et al. Prevalence and genotype distribution of Pneumocystis jirovecii in Cuban infants and toddlers with whooping cough. J Clin Microbiol 2014; 52 (01) 45-51
    CrossrefPubMedGoogle Scholar
  • 9 Vargas SL, Hughes WT, Santolaya ME. , et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001; 32 (06) 855-861
    CrossrefPubMedGoogle Scholar
  • 10 Respaldiza N, Medrano FJ, Medrano AC. , et al. High seroprevalence of Pneumocystis infection in Spanish children. Clin Microbiol Infect 2004; 10 (11) 1029-1031
    CrossrefPubMedGoogle Scholar
  • 11 Olsson M, Lidman C, Latouche S. , et al. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol 1998; 36 (06) 1737-1740
    CrossrefPubMedGoogle Scholar
  • 12 Ma L, Chen Z, Huang W. , et al. Genome analysis of three Pneumocystis species reveals adaptation mechanisms to life exclusively in mammalian hosts. Nat Commun 2016; 7: 10740
    CrossrefPubMedGoogle Scholar
  • 13 Aliouat-Denis CM, Chabé M, Demanche C. , et al. Pneumocystis species, co-evolution and pathogenic power. Infect Genet Evol 2008; 8 (05) 708-726
    CrossrefPubMedGoogle Scholar
  • 14 Chen W, Gigliotti F, Harmsen AG. Latency is not an inevitable outcome of infection with Pneumocystis carinii . Infect Immun 1993; 61 (12) 5406-5409
    CrossrefPubMedGoogle Scholar
  • 15 Totet A, Respaldiza N, Pautard JC, Raccurt C, Nevez G. Pneumocystis jiroveci genotypes and primary infection. Clin Infect Dis 2003; 36 (10) 1340-1342
    CrossrefPubMedGoogle Scholar
  • 16 An CL, Gigliotti F, Harmsen AG. Exposure of immunocompetent adult mice to Pneumocystis carinii f. sp. muris by cohousing: growth of P. carinii f. sp. muris and host immune response. Infect Immun 2003; 71 (04) 2065-2070
    CrossrefPubMedGoogle Scholar
  • 17 Gigliotti F, Wright TW. Pneumocystis: where does it live?. PLoS Pathog 2012; 8 (11) e1003025
    CrossrefPubMedGoogle Scholar
  • 18 Vargas SL, Ponce CA, Gigliotti F. , et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000; 38 (04) 1536-1538
    CrossrefPubMedGoogle Scholar
  • 19 Yiannakis EP, Boswell TC. Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control. J Hosp Infect 2016; 93 (01) 1-8
    CrossrefPubMedGoogle Scholar
  • 20 Montes-Cano MA, Chabe M, Fontillon-Alberdi M. , et al. Vertical transmission of Pneumocystis jirovecii in humans. Emerg Infect Dis 2009; 15 (01) 125-127
    CrossrefPubMedGoogle Scholar
  • 21 Vargas SL, Ponce CA, Gálvez P. , et al. Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr Infect Dis J 2007; 26 (01) 81-83
    CrossrefPubMedGoogle Scholar
  • 22 Pyrgos V, Shoham S, Roilides E, Walsh TJ. Pneumocystis pneumonia in children. Paediatr Respir Rev 2009; 10 (04) 192-198
    CrossrefPubMedGoogle Scholar
  • 23 Gigliotti F, Hughes WT. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988; 81 (06) 1666-1668
    CrossrefPubMedGoogle Scholar
  • 24 Hughes WT. Pneumocystis carinii pneumonia. Semin Pediatr Infect Dis 2001; 12: 309-314
    CrossrefPubMedGoogle Scholar
  • 25 Price RA, Hughes WT. Histopathology of Pneumocystis carinii infestation and infection in malignant disease in childhood. Hum Pathol 1974; 5 (06) 737-752
    CrossrefPubMedGoogle Scholar
  • 26 Morris A, Lundgren JD, Masur H. , et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10 (10) 1713-1720
    CrossrefPubMedGoogle Scholar
  • 27 Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 2007; 39 (6-7): 589-595
    CrossrefPubMedGoogle Scholar
  • 28 Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11 (06) 954-963
    CrossrefPubMedGoogle Scholar
  • 29 Fatti GL, Zar HJ, Swingler GH. Clinical indicators of Pneumocystis jiroveci pneumonia (PCP) in South African children infected with the human immunodeficiency virus. Int J Infect Dis 2006; 10 (04) 282-285
    CrossrefPubMedGoogle Scholar
  • 30 Kovacs JA, Hiemenz JW, Macher AM. , et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100 (05) 663-671
    CrossrefPubMedGoogle Scholar
  • 31 Richardson MD, Warnock DW. , eds. Pneumocystosis. Fungal Infection: Diagnosis and Management. 4th ed. NJ, USA: Blackwell Publishing Ltd; 2012: 264-276
    Google Scholar
  • 32 Kuhlman JE. Pneumocystic infections: the radiologist's perspective. Radiology 1996; 198 (03) 623-635
    CrossrefPubMedGoogle Scholar
  • 33 Crans Jr CA, Boiselle PM. Imaging features of Pneumocystis carinii pneumonia. Crit Rev Diagn Imaging 1999; 40 (04) 251-284
    CrossrefPubMedGoogle Scholar
  • 34 Kuhlman JE, Kavuru M, Fishman EK, Siegelman SS. Pneumocystis carinii pneumonia: spectrum of parenchymal CT findings. Radiology 1990; 175 (03) 711-714
    CrossrefPubMedGoogle Scholar
  • 35 Feuerstein IM, Francis P, Raffeld M, Pluda J. Widespread visceral calcifications in disseminated Pneumocystis carinii infection: CT characteristics. J Comput Assist Tomogr 1990; 14 (01) 149-151
    CrossrefPubMedGoogle Scholar
  • 36 Goodman PC. Pneumocystis carinii pneumonia. J Thorac Imaging 1991; 6 (04) 16-21
    CrossrefPubMedGoogle Scholar
  • 37 Kroe DM, Kirsch CM, Jensen WA. Diagnostic strategies for Pneumocystis carinii pneumonia. Semin Respir Infect 1997; 12 (02) 70-78
    PubMedGoogle Scholar
  • 38 Huang L, Morris A, Limper AH, Beck JM. ; ATS Pneumocystis Workshop Participants. An Official ATS Workshop Summary: recent advances and future directions in Pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006; 3 (08) 655-664
    CrossrefPubMedGoogle Scholar
  • 39 Lau WK, Young LS, Remington JS. Pneumocystis carinii pneumonia. Diagnosis by examination of pulmonary secretions. JAMA 1976; 236 (21) 2399-2402
    CrossrefPubMedGoogle Scholar
  • 40 Cruciani M, Marcati P, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 2002; 20 (04) 982-989
    CrossrefPubMedGoogle Scholar
  • 41 Limper AH, Offord KP, Smith TF, Martin II WJ. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140 (05) 1204-1209
    CrossrefPubMedGoogle Scholar
  • 42 Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am 2010; 24 (01) 107-138
    CrossrefPubMedGoogle Scholar
  • 43 Kovacs JA, Ng VL, Masur H. , et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med 1988; 318 (10) 589-593
    CrossrefPubMedGoogle Scholar
  • 44 Morrow BM, Samuel CM, Zampoli M, Whitelaw A, Zar HJ. Pneumocystis pneumonia in South African children diagnosed by molecular methods. BMC Res Notes 2014; 7: 26
    CrossrefPubMedGoogle Scholar
  • 45 Fujisawa T, Suda T, Matsuda H. , et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology 2009; 14 (02) 203-209
    CrossrefPubMedGoogle Scholar
  • 46 Flori P, Bellete B, Durand F. , et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 2004; 53 (Pt 7): 603-607
    CrossrefPubMedGoogle Scholar
  • 47 Tasaka S, Hasegawa N, Kobayashi S. , et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007; 131 (04) 1173-1180
    CrossrefPubMedGoogle Scholar
  • 48 Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259 (08) 1185-1189
    CrossrefPubMedGoogle Scholar
  • 49 Rieder MJ, King SM, Read S. Adverse reactions to trimethoprim-sulfamethoxazole among children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997; 16 (11) 1028-1031
    CrossrefPubMedGoogle Scholar
  • 50 Mofenson LM, Oleske J, Serchuk L, Van Dyke R, Wilfert C. ; CDC; National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53 (RR-14): 1-92
    PubMedGoogle Scholar
  • 51 Wharton JM, Coleman DL, Wofsy CB. , et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986; 105 (01) 37-44
    CrossrefPubMedGoogle Scholar
  • 52 Beck-Saue C, Dooley SW, Huton MD. , et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992; 268 (10) 1280-1286
    CrossrefPubMedGoogle Scholar
  • 53 Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015; (04) CD006150
    PubMedGoogle Scholar
  • 54 Sleasman JW, Hemenway C, Klein AS, Barret DJ. Corticosteroids improve survival of children with Acquired immunodeficiency syndrome and Pneumocystis carinii Pneumonia. Am J Dis Child 1993; 147 (01) 30-34
    PubMedGoogle Scholar
  • 55 National Institute of Health and Family Welfare. AIDS info. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/PedOIDosingTables.pdf . Accessed on April 4, 2017
    PubMedGoogle Scholar
  • 56 Bye MR, Bernstein LJ, Glaser J, Kleid D. Pneumocystis carinii pneumonia in young children with AIDS. Pediatr Pulmonol 1990; 9 (04) 251-253
    CrossrefPubMedGoogle Scholar
  • 57 Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001; 286 (19) 2450-2460
    CrossrefPubMedGoogle Scholar
  • 58 Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MF. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993; 270 (04) 470-473
    CrossrefPubMedGoogle Scholar
  • 59 World Health Organization (WHO). Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. Available at: http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf . Accessed on April 2, 2017
    PubMedGoogle Scholar
  • 60 Centre for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR Recomm Rep 1991; 40 (RR-2): 1-13
    PubMedGoogle Scholar
  • 61 Shankar SM, Nania JJ. Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs 2007; 9 (05) 301-309
    CrossrefPubMedGoogle Scholar
  • 62 Crozier F. Pneumocystis carinii pneumonia prophylaxis: current therapies and recommendations. J Pediatr Oncol Nurs 2011; 28 (03) 179-184
    CrossrefPubMedGoogle Scholar
  • 63 Cooley L, Dendle C, Wolf J. , et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014; 44 (12b): 1350-1363
    CrossrefPubMedGoogle Scholar
  • 64 Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014; (10) CD005590
    PubMedGoogle Scholar
  • 65 Grimwade K, Swingler G. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection. Cochrane Database Syst Rev 2003; (02) CD003508
    PubMedGoogle Scholar
  • 66 Hughes WT. Pneumocystis carinii infections in mothers, infants and non-AIDS elderly adults. Bailliere's. Clin Infect Dis 1995; 2: 461-470
    PubMedGoogle Scholar
  • 67 Minielly JA, Mills SD, Holley KE. Pneumocystis carinii pneumonia. Can Med Assoc J 1969; 100 (18) 846-854
    PubMedGoogle Scholar
  • 68 Western KA, Perera DR, Schultz MG. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1970; 73 (05) 695-702
    CrossrefPubMedGoogle Scholar
  • 69 Williams AJ, Duong T, McNally LM. , et al. Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection. AIDS 2001; 15 (03) 335-339
    CrossrefPubMedGoogle Scholar
  • 70 Bakeera-Kitaka S, Musoke P, Downing R, Tumwine JK. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann Trop Paediatr 2004; 24 (03) 227-235
    CrossrefPubMedGoogle Scholar
  • 71 Ling C, Qian S, Wang Q. , et al. Pneumocystis pneumonia in non-HIV children: A 10-year Retrospective Study. Clin Respir J 2016 ; [Epub ahead of print]
    PubMedGoogle Scholar